Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial

User: Guest

Title:: Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
Document type:: Zeitschriftenaufsatz
Author(s):: Fizazi, Karim; González Mella, Pablo; Castellano, Daniel; Minatta, Jose N.; Rezazadeh Kalebasty, Arash; Shaffer, David; Vázquez Limón, Juan C.; Sánchez López, Héctor M.; Armstrong, Andrew J.; Horvath, Lisa; Bastos, Diogo A.; Amin, Neha P.; Li, Jia; Unsal-Kacmaz, Keziban; Retz, Margitta; Saad, Fred; Petrylak, Daniel P.; Pachynski, Russell K.
Journal title:: European Journal of Cancer
Year:: 2022
Journal volume:: 160
Pages contribution:: 61-71
Fulltext / DOI:: doi:10.1016/j.ejca.2021.09.043
Publisher:: Elsevier BV
E-ISSN:: 0959-8049
Date of publication:: 01.01.2022
BibTeX

Occurrences: